Reported 2 days ago
Becton, Dickinson and Company (BDX) faced significant challenges in the second quarter of 2025, with earnings falling short of expectations due to reduced funding from the National Institutes of Health and uncertainty regarding future financial cuts. As a result, its stock saw a 23.62% decline over the past year and was marked as a major detractor in several investment portfolios.
Source: YAHOO